



1FW
Atty. Dkt. No. 034827-2301

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sun, et al.

Title: METHODS AND
COMPOSITIONS FOR THE
DETECTION OF
MUCOLIPIDOSIS IV
MUTATIONS

Appl. No.: 10/754,446

Filing Date: 01/09/2004

Examiner: Unknown

Art Unit: 1635

<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><u>DIANE GARCIA</u> (Printed Name)</p> <p><u>Diane Garcia</u> (Signature)</p> <p><u>6-23-04</u> (Date of Deposit)</p>
--

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment (IDS)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this

application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003*.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to

Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,


Date June 23, 2004

By Barry Wilson

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6722
Facsimile: (858) 792-6773

Barry S. Wilson
Attorney for Applicant
Registration No. 39,431

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/P
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/754,446
Filing Date	01/09/2004
First Named Inventor	Weimin Sun
Group Art Unit	1635
Examiner Name	Unknown
Attorney Docket Number	034827-2301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6,028,290		Yasuhara et al.	02-22-2000	
	A2	6,060,240		Kamb et al.	05-09-2000	
	A3	6,150,107		Glazer et al.	11-21-2000	
	A4	6,297,016		Egholm et al.	10-02-2001	
	A5	6,316,230		Egholm et al.	11-13-2001	
	A6	6,316,610		Lee et al.	11-13-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A7	Aldea et al., Rapid Detection of Herpes Simplex Virus DNA in Genital Ulcers by Real-time PCR Using SYBR Green I Dye as the Detection Signal, <i>J. Clin. Microbiol.</i> , 40:1060-1062 (2002).	
	A8	Bach, Mucopolipidosis Type IV, <i>Molecular Genetics and Metabolism</i> , 73:197-203, (2001).	
	A9	Bargal et al., Identification of the gene causing mucopolipidosis type IV, <i>Nature Genetics</i> , 26: 118-121, (2002).	


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/754,446
Filing Date	01/09/2004
First Named Inventor	Weimin Sun
Group Art Unit	1635
Examiner Name	Unknown
Attorney Docket Number	034827-2301

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A10	Bargal et al., Mucopolidosis Type IV: Novel MCOLN1 Mutations in Jewish and Non-Jewish Patients and the Frequency of the Disease in the Ashkenazi Jewish Population, <i>Human Mutation</i> , 17:397-402 (2001).	
	A11	Bassi et al., Cloning of the Gene Encoding a Novel Integral Membrane Protein, Mucopolidipin – and Identification Of the Two Major Founder Mutations Causing Mucopolidosis Type IV, <i>Am. J. Hum. Genet.</i> , 67:1110-1120, (2000).	
	A12	Dehée et al. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay, <i>J. Virological Methods</i> , 102:37-51, (2002).	
	A13	Hafner et al., Isothermal Amplification and Multimerization of DNA by <i>Bst</i> DNA Polymerase, <i>Biotechniques</i> , Apr.;30(4):852-6, 858, 860 passim, (2001).	
	A14	Saiki, "Amplification of Genomic DNA" in <i>PCR Protocols</i> , Innis et al., Eds., Academic Press, San Diego, CA 1990, pp 13-20.	
	A15	Sun et al., Mucopolidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel," <i>Human Molecular Genetics</i> , 9:2471-2478, (2000).	
	A16	Tyagi et al., Multicolor molecular beacons for allele discrimination, <i>Nature Biotechnology</i> , 16:49-53 (1998).	
	A17	Wharam et al., Specific detection of DNA and RNA targets using a novel isothermal nucleic acid amplification assay based on the formation of a three-way junction structure, <i>Nucleic Acids Res.</i> Jun 1;29(11):E54-E54,1-8, (2001).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.